 Cindy O'Bryant
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Agents | 21 | 2024 | 2061 | 1.870 |
Why?
| | Neoplasms | 31 | 2024 | 2470 | 1.720 |
Why?
| | Antiemetics | 2 | 2024 | 41 | 0.880 |
Why?
| | Pyridines | 5 | 2015 | 478 | 0.850 |
Why?
| | Piperidines | 3 | 2021 | 199 | 0.820 |
Why?
| | Indazoles | 1 | 2021 | 65 | 0.720 |
Why?
| | Anilides | 2 | 2013 | 73 | 0.710 |
Why?
| | Liver | 3 | 2021 | 1839 | 0.700 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 32 | 0.660 |
Why?
| | Immunoconjugates | 2 | 2023 | 103 | 0.650 |
Why?
| | Cisplatin | 5 | 2024 | 300 | 0.630 |
Why?
| | Morpholines | 1 | 2020 | 122 | 0.630 |
Why?
| | Drug Hypersensitivity | 1 | 2020 | 81 | 0.610 |
Why?
| | Pharmacists | 4 | 2017 | 247 | 0.560 |
Why?
| | Drug Interactions | 6 | 2024 | 394 | 0.560 |
Why?
| | Protein Kinase Inhibitors | 5 | 2024 | 891 | 0.550 |
Why?
| | Carcinoma, Basal Cell | 2 | 2017 | 74 | 0.520 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2019 | 209 | 0.510 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2020 | 1565 | 0.460 |
Why?
| | Receptor Protein-Tyrosine Kinases | 2 | 2015 | 231 | 0.460 |
Why?
| | Dose-Response Relationship, Drug | 13 | 2021 | 2012 | 0.410 |
Why?
| | Depsipeptides | 1 | 2012 | 13 | 0.400 |
Why?
| | Quinazolines | 2 | 2011 | 244 | 0.400 |
Why?
| | Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 43 | 0.390 |
Why?
| | Pyrazoles | 2 | 2013 | 405 | 0.380 |
Why?
| | Area Under Curve | 8 | 2021 | 304 | 0.370 |
Why?
| | Neuroendocrine Tumors | 1 | 2012 | 99 | 0.360 |
Why?
| | Sulindac | 2 | 2008 | 15 | 0.360 |
Why?
| | Nitriles | 2 | 2008 | 172 | 0.350 |
Why?
| | Sirolimus | 1 | 2012 | 266 | 0.350 |
Why?
| | Neoplasm Proteins | 2 | 2013 | 424 | 0.340 |
Why?
| | Aged | 30 | 2024 | 22103 | 0.330 |
Why?
| | Skin Neoplasms | 2 | 2017 | 825 | 0.330 |
Why?
| | Middle Aged | 33 | 2024 | 31154 | 0.330 |
Why?
| | Tosyl Compounds | 1 | 2008 | 16 | 0.300 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 51 | 0.300 |
Why?
| | Drug Dosage Calculations | 1 | 2008 | 22 | 0.290 |
Why?
| | Bone Density Conservation Agents | 1 | 2008 | 70 | 0.290 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2015 | 1052 | 0.290 |
Why?
| | Liver Failure, Acute | 1 | 2008 | 64 | 0.290 |
Why?
| | Androgen Antagonists | 1 | 2008 | 79 | 0.290 |
Why?
| | Breast Neoplasms | 3 | 2023 | 2142 | 0.270 |
Why?
| | Food | 1 | 2008 | 157 | 0.270 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7086 | 0.260 |
Why?
| | Fasting | 1 | 2008 | 267 | 0.260 |
Why?
| | Pain | 3 | 2011 | 789 | 0.260 |
Why?
| | Humans | 50 | 2024 | 129650 | 0.250 |
Why?
| | Liver Diseases | 2 | 2019 | 290 | 0.250 |
Why?
| | Acute Kidney Injury | 3 | 2018 | 790 | 0.250 |
Why?
| | Osteoporosis | 1 | 2008 | 232 | 0.240 |
Why?
| | Professional Role | 2 | 2017 | 158 | 0.240 |
Why?
| | Administration, Oral | 5 | 2012 | 786 | 0.240 |
Why?
| | Serotonin 5-HT3 Receptor Antagonists | 1 | 2024 | 5 | 0.240 |
Why?
| | Deoxycytidine | 5 | 2011 | 165 | 0.240 |
Why?
| | Female | 34 | 2024 | 68776 | 0.230 |
Why?
| | Pancreatic Neoplasms | 1 | 2012 | 882 | 0.230 |
Why?
| | Platinum | 1 | 2024 | 44 | 0.230 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1367 | 0.230 |
Why?
| | Maximum Tolerated Dose | 10 | 2020 | 193 | 0.230 |
Why?
| | Medical Oncology | 2 | 2017 | 272 | 0.220 |
Why?
| | Hedgehog Proteins | 2 | 2017 | 188 | 0.220 |
Why?
| | Adult | 27 | 2024 | 35576 | 0.220 |
Why?
| | Nausea | 4 | 2020 | 110 | 0.220 |
Why?
| | Midazolam | 1 | 2024 | 53 | 0.220 |
Why?
| | Male | 33 | 2024 | 63681 | 0.220 |
Why?
| | Lung Neoplasms | 2 | 2015 | 2344 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 4 | 2010 | 220 | 0.210 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2024 | 87 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2017 | 759 | 0.210 |
Why?
| | Vomiting | 3 | 2020 | 128 | 0.200 |
Why?
| | Cohort Studies | 5 | 2020 | 5420 | 0.180 |
Why?
| | Lymphoma | 2 | 2016 | 196 | 0.180 |
Why?
| | Sulfonamides | 2 | 2019 | 496 | 0.180 |
Why?
| | ErbB Receptors | 2 | 2017 | 607 | 0.180 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2023 | 197 | 0.180 |
Why?
| | Prostatic Neoplasms | 1 | 2008 | 1016 | 0.180 |
Why?
| | Pyrimidines | 2 | 2024 | 459 | 0.170 |
Why?
| | Trastuzumab | 2 | 2023 | 101 | 0.170 |
Why?
| | Apoptosis | 3 | 2008 | 2503 | 0.170 |
Why?
| | Fluorouracil | 4 | 2011 | 199 | 0.170 |
Why?
| | Benzoxazoles | 1 | 2020 | 20 | 0.170 |
Why?
| | Drug Evaluation | 1 | 2020 | 82 | 0.170 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2008 | 1279 | 0.170 |
Why?
| | Analgesics, Opioid | 1 | 2008 | 913 | 0.160 |
Why?
| | Azepines | 1 | 2020 | 89 | 0.160 |
Why?
| | Hydroxamic Acids | 1 | 2019 | 88 | 0.160 |
Why?
| | TWEAK Receptor | 1 | 2017 | 5 | 0.140 |
Why?
| | Models, Biological | 1 | 2024 | 1722 | 0.140 |
Why?
| | Pharmacogenomic Variants | 1 | 2017 | 35 | 0.140 |
Why?
| | Hematology | 1 | 2017 | 14 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2014 | 530 | 0.140 |
Why?
| | Academic Medical Centers | 1 | 2020 | 481 | 0.130 |
Why?
| | Schools, Pharmacy | 1 | 2017 | 46 | 0.130 |
Why?
| | Pharmaceutical Services | 1 | 2017 | 81 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 327 | 0.130 |
Why?
| | Maytansine | 1 | 2016 | 16 | 0.130 |
Why?
| | Aminoglycosides | 1 | 2016 | 23 | 0.130 |
Why?
| | Specialty Boards | 1 | 2016 | 32 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2742 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2017 | 312 | 0.120 |
Why?
| | Drugs, Investigational | 1 | 2015 | 32 | 0.120 |
Why?
| | Biomarkers, Tumor | 4 | 2010 | 1181 | 0.120 |
Why?
| | Phenylurea Compounds | 1 | 2015 | 89 | 0.120 |
Why?
| | Prescription Drugs | 1 | 2016 | 112 | 0.120 |
Why?
| | American Heart Association | 1 | 2016 | 296 | 0.120 |
Why?
| | Carbazoles | 1 | 2015 | 84 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 431 | 0.110 |
Why?
| | Education, Pharmacy, Graduate | 1 | 2014 | 17 | 0.110 |
Why?
| | Insurance Claim Review | 1 | 2014 | 64 | 0.110 |
Why?
| | Drug Administration Schedule | 5 | 2019 | 769 | 0.110 |
Why?
| | Carboplatin | 3 | 2009 | 140 | 0.110 |
Why?
| | Chronic Pain | 1 | 2017 | 254 | 0.100 |
Why?
| | Specialization | 1 | 2014 | 145 | 0.100 |
Why?
| | Gonanes | 1 | 2012 | 27 | 0.100 |
Why?
| | Everolimus | 1 | 2012 | 88 | 0.100 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2010 | 339 | 0.100 |
Why?
| | Signal Transduction | 2 | 2017 | 4925 | 0.090 |
Why?
| | Clinical Trials as Topic | 2 | 2015 | 1004 | 0.090 |
Why?
| | Biomarkers | 3 | 2018 | 3973 | 0.090 |
Why?
| | Erlotinib Hydrochloride | 1 | 2011 | 70 | 0.090 |
Why?
| | Drug Monitoring | 1 | 2013 | 216 | 0.090 |
Why?
| | Liver Function Tests | 1 | 2011 | 112 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 827 | 0.090 |
Why?
| | Phytotherapy | 1 | 2011 | 79 | 0.090 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2014 | 248 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2020 | 14518 | 0.090 |
Why?
| | Curriculum | 1 | 2017 | 917 | 0.090 |
Why?
| | Glucuronidase | 2 | 2008 | 44 | 0.080 |
Why?
| | Heart Ventricles | 1 | 2015 | 781 | 0.080 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 485 | 0.080 |
Why?
| | Anti-Anxiety Agents | 1 | 2010 | 45 | 0.080 |
Why?
| | Treatment Outcome | 7 | 2015 | 10230 | 0.080 |
Why?
| | Neoplasm Invasiveness | 1 | 2011 | 485 | 0.080 |
Why?
| | Oligosaccharides | 2 | 2008 | 57 | 0.080 |
Why?
| | Clinical Competence | 1 | 2017 | 1017 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2010 | 84 | 0.080 |
Why?
| | Kidney | 1 | 2017 | 1385 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2012 | 396 | 0.080 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2009 | 29 | 0.080 |
Why?
| | Primary Health Care | 2 | 2017 | 1680 | 0.080 |
Why?
| | Cannabinoids | 1 | 2011 | 153 | 0.080 |
Why?
| | Cell Proliferation | 1 | 2017 | 2391 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2016 | 592 | 0.080 |
Why?
| | Capecitabine | 4 | 2011 | 46 | 0.080 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2008 | 3 | 0.080 |
Why?
| | Equipment and Supplies | 1 | 2008 | 41 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1501 | 0.070 |
Why?
| | Taxoids | 2 | 2008 | 98 | 0.070 |
Why?
| | Boronic Acids | 1 | 2008 | 37 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 106 | 0.070 |
Why?
| | Community Pharmacy Services | 1 | 2008 | 43 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2008 | 68 | 0.070 |
Why?
| | Marijuana Smoking | 1 | 2011 | 247 | 0.070 |
Why?
| | Etoposide | 1 | 2008 | 148 | 0.070 |
Why?
| | Farnesyltranstransferase | 1 | 2007 | 35 | 0.070 |
Why?
| | Drug Prescriptions | 1 | 2010 | 248 | 0.070 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2008 | 79 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2010 | 297 | 0.070 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 57 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 177 | 0.070 |
Why?
| | Receptors, Vitronectin | 1 | 2007 | 9 | 0.070 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 124 | 0.070 |
Why?
| | Integrin alphaVbeta3 | 1 | 2007 | 19 | 0.070 |
Why?
| | Absorptiometry, Photon | 1 | 2008 | 248 | 0.070 |
Why?
| | Snake Venoms | 1 | 2007 | 21 | 0.070 |
Why?
| | Pyrazines | 1 | 2008 | 86 | 0.070 |
Why?
| | Oxycodone | 1 | 2008 | 43 | 0.070 |
Why?
| | Benzamides | 1 | 2008 | 207 | 0.070 |
Why?
| | Indoles | 2 | 2008 | 387 | 0.070 |
Why?
| | Fatigue | 4 | 2012 | 318 | 0.070 |
Why?
| | Fentanyl | 1 | 2008 | 79 | 0.070 |
Why?
| | Triazoles | 1 | 2008 | 152 | 0.070 |
Why?
| | Palliative Care | 2 | 2011 | 725 | 0.070 |
Why?
| | Delayed-Action Preparations | 1 | 2008 | 173 | 0.070 |
Why?
| | Animals | 6 | 2020 | 35361 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2010 | 356 | 0.070 |
Why?
| | Integrins | 1 | 2007 | 94 | 0.070 |
Why?
| | Morphine | 1 | 2008 | 137 | 0.070 |
Why?
| | Young Adult | 3 | 2020 | 12426 | 0.070 |
Why?
| | Methadone | 1 | 2008 | 92 | 0.070 |
Why?
| | Pharmacogenetics | 1 | 2008 | 175 | 0.070 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2007 | 119 | 0.070 |
Why?
| | Cell Line, Tumor | 3 | 2020 | 3215 | 0.070 |
Why?
| | Thiophenes | 1 | 2007 | 118 | 0.060 |
Why?
| | Alkyl and Aryl Transferases | 1 | 2006 | 53 | 0.060 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 118 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2008 | 582 | 0.060 |
Why?
| | Societies, Pharmaceutical | 2 | 2017 | 21 | 0.060 |
Why?
| | Risk Factors | 1 | 2020 | 9765 | 0.060 |
Why?
| | Creatinine | 2 | 2018 | 491 | 0.060 |
Why?
| | Protein Binding | 1 | 2011 | 2121 | 0.060 |
Why?
| | Granisetron | 1 | 2024 | 5 | 0.060 |
Why?
| | Quinuclidines | 1 | 2024 | 9 | 0.060 |
Why?
| | Ondansetron | 1 | 2024 | 15 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2008 | 524 | 0.060 |
Why?
| | United States | 5 | 2017 | 13903 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1242 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 814 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2008 | 299 | 0.060 |
Why?
| | Isoquinolines | 1 | 2024 | 41 | 0.060 |
Why?
| | Quinolones | 1 | 2006 | 126 | 0.060 |
Why?
| | Cannabis | 1 | 2011 | 465 | 0.060 |
Why?
| | Infusions, Intravenous | 2 | 2019 | 400 | 0.060 |
Why?
| | RNA, Catalytic | 1 | 2005 | 185 | 0.060 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 711 | 0.060 |
Why?
| | Prospective Studies | 3 | 2024 | 7133 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 759 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2015 | 2004 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 109 | 0.050 |
Why?
| | Heart Failure | 1 | 2016 | 2150 | 0.050 |
Why?
| | Pyrroles | 1 | 2024 | 202 | 0.050 |
Why?
| | Diarrhea | 2 | 2015 | 180 | 0.050 |
Why?
| | Adolescent | 2 | 2020 | 20393 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2008 | 1368 | 0.050 |
Why?
| | Receptor, ErbB-2 | 1 | 2023 | 326 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1295 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2020 | 55 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 62 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 119 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 136 | 0.040 |
Why?
| | Organic Cation Transporter 2 | 1 | 2017 | 8 | 0.040 |
Why?
| | Glutathione S-Transferase pi | 1 | 2017 | 9 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2017 | 37 | 0.040 |
Why?
| | Anemia | 2 | 2009 | 160 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2008 | 5066 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 315 | 0.030 |
Why?
| | Partial Thromboplastin Time | 2 | 2008 | 52 | 0.030 |
Why?
| | Organic Cation Transport Proteins | 1 | 2017 | 30 | 0.030 |
Why?
| | Amidine-Lyases | 1 | 1997 | 1 | 0.030 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2007 | 24 | 0.030 |
Why?
| | Mixed Function Oxygenases | 1 | 1997 | 41 | 0.030 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 1997 | 52 | 0.030 |
Why?
| | Multienzyme Complexes | 1 | 1997 | 68 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2017 | 152 | 0.030 |
Why?
| | Paclitaxel | 2 | 2009 | 217 | 0.030 |
Why?
| | Cation Transport Proteins | 1 | 2017 | 132 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 5406 | 0.030 |
Why?
| | Regression Analysis | 1 | 2018 | 993 | 0.030 |
Why?
| | Cardiotoxins | 1 | 2015 | 4 | 0.030 |
Why?
| | Drug Eruptions | 1 | 2015 | 27 | 0.030 |
Why?
| | Mucositis | 1 | 2015 | 19 | 0.030 |
Why?
| | Education, Pharmacy | 1 | 2017 | 119 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 354 | 0.030 |
Why?
| | Analgesics | 1 | 1997 | 189 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4897 | 0.030 |
Why?
| | Pharmacy Residencies | 1 | 2014 | 11 | 0.030 |
Why?
| | Drug Discovery | 1 | 2015 | 131 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1698 | 0.030 |
Why?
| | Students, Pharmacy | 1 | 2014 | 96 | 0.030 |
Why?
| | Stroke Volume | 1 | 2015 | 592 | 0.020 |
Why?
| | Electrocardiography | 1 | 2015 | 608 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2016 | 504 | 0.020 |
Why?
| | Dioxoles | 1 | 2011 | 9 | 0.020 |
Why?
| | Tetrahydroisoquinolines | 1 | 2011 | 8 | 0.020 |
Why?
| | Biological Availability | 1 | 2011 | 147 | 0.020 |
Why?
| | Mice | 3 | 2020 | 16937 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3381 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2012 | 359 | 0.020 |
Why?
| | Massage | 1 | 2010 | 43 | 0.020 |
Why?
| | Alopecia | 1 | 2009 | 30 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3794 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 70 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2014 | 608 | 0.020 |
Why?
| | Celecoxib | 1 | 2008 | 39 | 0.020 |
Why?
| | Bortezomib | 1 | 2008 | 45 | 0.020 |
Why?
| | Maximum Allowable Concentration | 1 | 2008 | 14 | 0.020 |
Why?
| | Floxuridine | 1 | 2008 | 5 | 0.020 |
Why?
| | Protein Kinase C beta | 1 | 2008 | 21 | 0.020 |
Why?
| | Guidelines as Topic | 1 | 2010 | 264 | 0.020 |
Why?
| | Platelet Factor 4 | 1 | 2008 | 34 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 85 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2007 | 124 | 0.020 |
Why?
| | Matrix Metalloproteinase Inhibitors | 1 | 2007 | 15 | 0.020 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2008 | 123 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2007 | 55 | 0.020 |
Why?
| | Protein Prenylation | 1 | 2006 | 34 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 27 | 0.020 |
Why?
| | Carcinoid Tumor | 1 | 2006 | 24 | 0.020 |
Why?
| | Protein Kinase C | 1 | 2008 | 259 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2008 | 186 | 0.020 |
Why?
| | Heparin | 1 | 2008 | 253 | 0.020 |
Why?
| | Cell Adhesion Molecules | 1 | 2007 | 173 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2006 | 91 | 0.020 |
Why?
| | Risk | 1 | 2008 | 854 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 198 | 0.020 |
Why?
| | Inflammation | 1 | 1997 | 2736 | 0.020 |
Why?
| | Fibroblast Growth Factors | 1 | 2006 | 170 | 0.010 |
Why?
| | Antibody Formation | 1 | 2006 | 290 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 2008 | 1206 | 0.010 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2005 | 107 | 0.010 |
Why?
| | Monocytes | 1 | 2008 | 551 | 0.010 |
Why?
| | Disease Progression | 1 | 2012 | 2635 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2006 | 180 | 0.010 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 253 | 0.010 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2004 | 187 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1713 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2004 | 185 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1472 | 0.010 |
Why?
| | Endothelial Cells | 1 | 2007 | 749 | 0.010 |
Why?
| | Mutation | 1 | 2012 | 3717 | 0.010 |
Why?
| | Melanoma | 1 | 2006 | 730 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2006 | 752 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2010 | 3408 | 0.010 |
Why?
| | Carrageenan | 1 | 1997 | 8 | 0.010 |
Why?
| | Lyases | 1 | 1997 | 9 | 0.010 |
Why?
| | Bradykinin | 1 | 1997 | 45 | 0.010 |
Why?
| | Substance P | 1 | 1997 | 43 | 0.010 |
Why?
| | Edema | 1 | 1997 | 124 | 0.010 |
Why?
| | Substrate Specificity | 1 | 1997 | 368 | 0.010 |
Why?
| | Serotonin | 1 | 1997 | 321 | 0.010 |
Why?
| | Time Factors | 1 | 2004 | 6556 | 0.010 |
Why?
| | Kinetics | 1 | 1997 | 1642 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2058 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 1997 | 2406 | 0.010 |
Why?
| | Rats | 1 | 1997 | 5500 | 0.000 |
Why?
|
|
O'Bryant's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|